Four Breakthrough Drugs Could Change Primary Care—But at High Cost

At the ACP-IM Meeting 2026, experts highlight four 2025 drug approvals with potential to change primary care: tradipitant for motion-sickness vomiting (new neurokinin-1 antagonist; price likely >$500 for an eight-tablet supply and not approved for prevention of nausea), suzetrigine as a first non-opioid option for acute postoperative pain with opioid-level relief but limited long-term data, gepotidacin for uncomplicated UTIs showing noninferiority to nitrofurantoin and better activity against resistant bugs yet costing about $2,000 for a 5-day course, and remibrutinib for refractory chronic spontaneous urticaria with sustained 24-week improvements but high 30-day costs and a need for more postmarketing safety data and head-to-head comparisons with biologics. The drugs could shift practice, but access, cost, and further comparative studies will determine their ultimate impact relative to current standards like scopolamine, nitrofurantoin, and injectable biologics.